<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415749</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-201-102</org_study_id>
    <secondary_id>HHSO100201600008C</secondary_id>
    <nct_id>NCT04415749</nct_id>
  </id_info>
  <brief_title>NasoShield in Healthy Adults to Study Safety and Immunogenicity</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Study of the Safety and Immunogenicity of NasoShield Administered as One or Two Doses in Different Dosing Positions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety for up to two doses of NasoShield, to&#xD;
      determine if antibodies that protect against anthrax are formed after treatment with&#xD;
      NasoShield, and to determine whether the formation of these antibodies are affected by&#xD;
      different positions of administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all healthy volunteers that have&#xD;
      given written informed consent will undergo screening to determine eligibility for study&#xD;
      entry. If the healthy volunteer qualifies for the study, they will be randomly assigned to 1&#xD;
      of 3 treatment groups. Within the treatment group, the participant will be randomized in a&#xD;
      double-blind manner in a 5:2 ratio to NasoShield or placebo.&#xD;
&#xD;
      The investigational drug (either NasoShield or placebo) will be administered on Days 1 and 29&#xD;
      after qualifying into the study. The position of administration and the amount of time the&#xD;
      subject will need to stay in the specified position will depend on the group to which the&#xD;
      subject is assigned.&#xD;
&#xD;
      Participants will return to the investigational site for multiple visits through Day 210&#xD;
      (approximately 6 months after the second dose). At each visit, the participant will be asked&#xD;
      about interim medical history and use of any medications, and safety and immunogenicity&#xD;
      assessments will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Actual">March 3, 2021</completion_date>
  <primary_completion_date type="Actual">March 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 parallel groups defined by dosing position and number of doses</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reactogenicity to evaluate the safety of NasoShield</measure>
    <time_frame>For 7 days after vaccination</time_frame>
    <description>Subjects will record solicited local and systemic events for 7 days after each dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events (AEs) to evaluate the safety of NasoShield</measure>
    <time_frame>From Day 1 to Day 210</time_frame>
    <description>All adverse events from Day 1 to Day 57; serious adverse events (SAE), medically attended adverse events (MAAE), and new-onset chronic illnesses (NCI) from Day 1 to Day 210</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-protective antigen (PA) immunoglobulin G (IgG) to evaluate humoral immunogenicity</measure>
    <time_frame>From Day 1 to Day 210</time_frame>
    <description>Titer measured by enzyme-linked immunosorbent assay (ELISA) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxin neutralization antibody 50% neutralization factor (TNA-NF50) titer measured in serum by cytotoxic assay to evaluate humoral immunogenicity</measure>
    <time_frame>From Day 1 to Day 210</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-protective antigen (PA) immunoglobulin A (IgA) to evaluate mucosal immune response</measure>
    <time_frame>From Day 1 to Day 57</time_frame>
    <description>Titer measured by enzyme-linked immunosorbent assay (ELISA) in serum</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>NasoShield One Dose in Position 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NasoShield on Day 1 and saline placebo on Day 29 in position 1 (Group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Position 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo on Day 1 and saline placebo on Day 29 in position 1 (Group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoShield Two Doses in Position 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NasoShield on Day 1 and Day 29 in position 2 (Group 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Position 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo on Day 1 and Day 29 in position 2 (Group 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NasoShield Two Doses in Position 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NasoShield on Day 1 and Day 29 in position 3 (Group 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in Position 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo on Day 1 and Day 29 in position 3 (Group 3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NasoShield</intervention_name>
    <description>NasoShield is an adenovirus-vectored anthrax vaccine</description>
    <arm_group_label>NasoShield One Dose in Position 1</arm_group_label>
    <arm_group_label>NasoShield Two Doses in Position 2</arm_group_label>
    <arm_group_label>NasoShield Two Doses in Position 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>NasoShield One Dose in Position 1</arm_group_label>
    <arm_group_label>Placebo in Position 1</arm_group_label>
    <arm_group_label>Placebo in Position 2</arm_group_label>
    <arm_group_label>Placebo in Position 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women 18 to 49 years of age, inclusive&#xD;
&#xD;
          2. Good general health status&#xD;
&#xD;
          3. Adequate venous access for repeated phlebotomies&#xD;
&#xD;
          4. Screening laboratory results within institutional normal range or Grade 1 abnormality&#xD;
             if the Investigator documents clinical insignificance. Creatine kinase or bilirubin&#xD;
             may be Grade 2 if associated with normal alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) and the Investigator considers the result not to be clinically&#xD;
             significant due to vigorous exercise or Gilbert's syndrome&#xD;
&#xD;
          5. Negative drug and alcohol screen at Screening and predose on Day 1&#xD;
&#xD;
          6. For women who have not been surgically sterilized or who do not have laboratory&#xD;
             confirmation of postmenopausal status, negative pregnancy test&#xD;
&#xD;
          7. Willingness to practice a highly effective method of contraception that may include,&#xD;
             but is not limited to, abstinence, sex only with persons of the same sex, monogamous&#xD;
             relationship with a postmenopausal partner, monogamous relationship with vasectomized&#xD;
             partner, vasectomy, surgical sterilization (hysterectomy, bilateral tubal ligation,&#xD;
             salpingectomy, or oophorectomy), licensed hormonal methods, intrauterine device (IUD),&#xD;
             or consistent use of a barrier method (eg, condom, diaphragm) with spermicide for 28&#xD;
             days after the last IP dose&#xD;
&#xD;
          8. Willingness to participate and comply with all aspects of the study through the entire&#xD;
             study period, including nasopharyngeal swabs and blood and urine samples&#xD;
&#xD;
          9. Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, possibly pregnant, or lactating women&#xD;
&#xD;
          2. Body mass index &gt; 35.0 kg/m2&#xD;
&#xD;
          3. Positive result for HIV, hepatitis B virus, or hepatitis C virus at Screening&#xD;
&#xD;
          4. Asthma or other chronic lung disease that is greater than mild in severity.&#xD;
             Specifically excluded are participants with any of the following events in the past&#xD;
             year:&#xD;
&#xD;
               -  Daily symptoms&#xD;
&#xD;
               -  Daily use of short acting beta 2 agonists&#xD;
&#xD;
               -  Use of inhaled steroids or theophylline&#xD;
&#xD;
               -  Use of pulse systemic steroids&#xD;
&#xD;
               -  Emergency care or hospitalization related to asthma or other chronic lung disease&#xD;
&#xD;
               -  Systemic steroids for asthma exacerbation&#xD;
&#xD;
          5. History of diabetes mellitus (gestational diabetes is allowed if treatment was not&#xD;
             required postpartum and serum glucose is currently in the normal range)&#xD;
&#xD;
          6. History of coronary artery disease, arrhythmia, or congestive heart failure&#xD;
&#xD;
          7. Clinically significant ECG abnormality&#xD;
&#xD;
          8. Poorly controlled hypertension (systolic blood pressure &gt; 150 mmHg or diastolic blood&#xD;
             pressure &gt; 95 mmHg) at Screening or predose on Day 1&#xD;
&#xD;
          9. History of anaphylaxis or angioedema&#xD;
&#xD;
         10. Known allergy to any of the ingredients in the vaccine formulation&#xD;
&#xD;
         11. Known allergy or sensitivity to latex&#xD;
&#xD;
         12. History of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or other&#xD;
             nasal abnormality that might affect vaccine administration&#xD;
&#xD;
         13. Previous nasal surgery or nasal cauterization&#xD;
&#xD;
         14. Any symptoms of upper respiratory infection or temperature &gt; 38Â°C within 3 days before&#xD;
             Day 1&#xD;
&#xD;
         15. Any symptoms within 24 hours before Day 1 of upper respiratory illness or allergy&#xD;
             flare-up that, in the opinion of the Investigator, presents as nasal congestion or&#xD;
             rhinorrhea that could inhibit the proper administration of the IP&#xD;
&#xD;
         16. Known or suspected malignancy, excluding non-melanoma skin cancers and other early&#xD;
             stage surgically excised malignancies that the Investigator considers to be&#xD;
             exceedingly unlikely to recur&#xD;
&#xD;
         17. Immunocompromised individuals, including those who have used corticosteroids(including&#xD;
             intranasal steroids), alkylating drugs, antimetabolites, radiation, immune-modulating&#xD;
             biologics, or other immunomodulating therapies within 90 days before Day 1 or those&#xD;
             who plan use during the study period&#xD;
&#xD;
         18. History of autoimmune or demyelinating disease&#xD;
&#xD;
         19. Use of statin medication within 30 days before Day 1 (see list in Section 6.7.1)&#xD;
&#xD;
         20. Receipt of intranasal medications (including over-the-counter medications) within 30&#xD;
             days before Day 1&#xD;
&#xD;
         21. Receipt of any IP within 30 days before Day 1&#xD;
&#xD;
         22. Receipt of any vaccine within 30 days before Day 1&#xD;
&#xD;
         23. Receipt of intranasal vaccine within 90 days before Day 1&#xD;
&#xD;
         24. Receipt of any licensed or investigational anthrax vaccine in civilian or military&#xD;
             life&#xD;
&#xD;
         25. Any change in medication for a chronic medical condition within 30 days before Day 1&#xD;
&#xD;
         26. Past regular use or current use of intranasal illicit drugs&#xD;
&#xD;
         27. Any medical, psychiatric, or social condition or occupational or other responsibility&#xD;
             that in the judgment of the Investigator would interfere with or serve as a&#xD;
             contraindication to protocol adherence, assessment of safety (including&#xD;
             reactogenicity), or a subject's ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anthrax</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

